Sign in
Not yet taking people in United StatesPhase 2

PSMA PET/MRI scans to find prostate cancer and predict treatment response

Tests a PET/MRI scan with 18F-DCFPyL to detect prostate cancer in men.

Key facts

Who runs it
University of Wisconsin, Madison
Where
Madison, United StatesSee the site
Trial code
Registry title
PSMA PET/MRI for Predicting and Detecting Prostate Cancer
Status
Not yet recruiting
Phase
Phase 2
People taking part
120 people, planned
Starts
Dec 2026
Expected to end
Dec 2031
Type of study
Interventional, 2 groups
Treatments tested
  • PSMA PET
  • MRI
  • 18F-DCFPyL
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer. One group has high-risk disease before treatment. The other has very low to intermediate-risk disease. Both groups have PSMA PET/MRI scans with 18F-DCFPyL.

Age
Sub-study 1: 18 years or older. Sub-study 2: 40 to 85 years.
Sex
Men only.
Disease stage
Sub-study 1: newly diagnosed high-risk prostate cancer (Gleason 8-10 or PSA>20) or oligometastatic (fewer than 10 sites). Sub-study 2: very low to intermediate-risk cancer (T1c to T2, Gleason group 1 to 3, any PSA).
Earlier treatment
Sub-study 1: no earlier treatment of the main disease. Hormone therapy (LHRH or ARSI) may have started, but not more than 30 days before joining. Sub-study 2: no pelvic radiation, chemotherapy or hormone therapy for prostate cancer.

Main reasons for not taking part

  • Castration-resistant prostate cancer, or cancer in organs or the brain (sub-study 1)
  • Another active cancer in the past 2 years, with a few exceptions
  • Cannot have MRI or contrast dye, or cannot lie flat for the scan
  • Needs intravenous sedation for imaging
  • Other cancer trial treatment at the same time (sub-study 1)

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • Participant must be ≥ 18 years of age
  • Participant must have an ECOG performance status ≤ 1
  • High risk disease (NCCN criteria Gleason 8-10 or PSA>20) or oligometastatic
  • Histologic confirmation of prostate adenocarcinoma of the prostate gland, with or without evidence of metastases (oligometastatic <10 sites) on imaging by conventional imaging (MRI, CT, or 99mTc bone scan) or PSMA PET/CT
  • Newly diagnosed disease with no prior treatment (surgery, radiation or systemic treatment, hormone therapy or chemotherapy) to the primary disease; Participants may have started LHRH agonist or antagonist therapy, and/or androgen receptor signaling inhibitor (ARSI) as long as it was not started more than 30 days before the patient is enrolled on this study
  • Participants will have i) enrolled on the METANOVA trial or ii) have selected androgen deprivation therapy prior to surgery as their treatment of choice
  • Ability to understand and the willingness to sign a written informed consent
  • Male, 40-85 years of age
  • New diagnosis of prostate cancer undergoing additional biopsy evaluation or high clinical suspicion of prostate cancer with elevated and rising PSA level
  • Participant with prostate cancer undergoing:; Reevaluation for progression on active surveillance or watchful waiting as manifest by rising PSA and/or change in digital-rectal exam OR; Participant on active surveillance or watchful waiting undergoing planned MRI/TRUS prostate biopsy for re-evaluation
  • Meet criteria ranging from very low to intermediate risk group:; T1c to T2; Gleason-group (GG) 1 (Gleason score 6), GG2 (Gleason score 3+4) or GG3 (Gleason score 4+3) prostate adenocarcinoma; Any PSA permitted
  • Karnofsky performance status of at least 70
  • General health and anatomy suitable to undergo transrectal ultrasound-MRI fusion biopsy, as determined by SOC, of the identified lesions and standard 12 core sextent biopsy
  • Ability to understand and the willingness to sign a written informed consent

Who cannot take part

  • Participant receiving any other investigational agents for cancer
  • Participant is participating in a concurrent treatment protocol for cancer
  • Contraindications to MRI or intravenous contrast administration per institutional MRI safety screening including severe kidney disease, prior severe allergic reaction to gadolinium-based contrast, prior nephrogenic systemic fibrosis
  • Prior definitive treatment to the primary prostate cancer or pelvis. Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes (HgA1c > 10), active pituitary or adrenal dysfunction, or psychiatric illness/social situations that would limit compliance with study requirements
  • History of another active malignancy within the previous 2 years, except for non-melanoma skin cancer, non-muscle invasive bladder cancer, or a malignancy that is considered cured with minimal risk of recurrence
  • Participants requiring intravenous (IV) conscious sedation for imaging are not eligible; participants requiring mild, oral anxiolytics for the clinical MRI scan will be allowed to participate as long as the following criteria are met:; The participant has their own prescription for the medication; The informed consent process is conducted prior to the self-administration of the medication; The participant comes to the research visit with a driver or an alternative plan for transportation (e.g. Uber, taxi, etc.)
  • Prior pelvic external beam radiation therapy or brachytherapy
  • Prior history of any other malignancy within the last 2 years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer
  • Contraindications to MRI or intravenous contrast administration per institutional MRI safety screening including severe kidney disease, prior severe allergic reaction to gadolinium-based contrast, prior nephrogenic systemic fibrosis
  • Participants requiring intravenous (IV) conscious sedation for imaging are not eligible; participants requiring mild, oral anxiolytics for the clinical MRI scan will be allowed to participate as long as the following criteria are met:; The participant has their own prescription for the medication; The informed consent process is conducted prior to the self-administration of the medication; The participant comes to the research visit with a driver or an alternative plan for transportation (e.g. Uber, taxi, etc.)
  • Castration resistant prostate cancer (CRPC)
  • Active Crohn's disease or ulcerative colitis despite medical management
  • Any condition that in the opinion of the investigator would preclude participation in this study
  • Chemotherapy for prostate cancer
  • Androgen deprivation therapy for prostate cancer
  • Evidence of visceral or intracranial metastases
  • Unable to lie flat during or tolerate PET/MRI
  • Refusal to sign informed consent
  • Unable to lie flat during or tolerate PET/MRI

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Where in United States

  • University of Wisconsin - MadisonMadison, United StatesContact: Abigail WiedmerNot yet recruiting

About the trial

What the trial wants to find out

The goal of this clinical trial is to see if a drug called 18F-DCFPyL can help find prostate cancer or prostate cancer that has spread to other parts of the body. The main question it aims to answer is:

Read full original descriptionShow less

* Can 18F-DCFPyL predict response to therapy; and, * Does 18F-DCFPyL improve detection of early signs of cancer.

Participants will undergo PET/MRI scans.

The 2 groups in the trial

  • Men with high-risk prostate cancer (Study 1)Treatment being tested

    Men with high-risk prostate cancer will undergo PSMA PET and MRI

    Treatment: PSMA PET, MRI, and 18F-DCFPyL

  • Men with very low to intermediate risk prostate cancer (Study 2)Treatment being tested

    Men with very low to intermediate risk prostate cancer will undergo PSMA PET and MRI

    Treatment: PSMA PET, MRI, and 18F-DCFPyL

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
PSMA PET/MRI to Predict Tumor Response to Neoadjuvant Systemic Therapy in Men With High-Risk Prostate Cancer, and Detection of Cancer in Men With Very Low to Intermediate-Risk Prostate Cancer
Plain-language title
PSMA PET/MRI scans to find prostate cancer and predict treatment responseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07924605, who can take part
Record updated
9 November 2026